Kijkboek schreef op 8 juni 2021 03:05:
Immutep Reveals a New anti-LAG-3 Research Program
SYDNEY, AUSTRALIA – 8 June 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), the leading developer of LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to provide an update on its preclinical development pipeline.
www.immutep.com/files/content/investo...